Company intelligence / Profile preview

Respiratorius AB

Ownership: Private
Employees: ~1
Development stage: Other

Overview

VAL001 demonstrated significantly higher two-year survival in DLBCL patients when used as a pre-treatment with standard therapy compared to standard therapy alone. The company has secured Orphan Drug Designation and additional patents for VAL001. EMA has recommended moving directly from phase I/IIa to phase III studies. Partnering discussions are ongoing

Therapeutic areas: OncologyPulmonology
Modalities: small molecules (notably oral sodium valproate formulation)
Industry: Biotech

Drug pipeline

3 assets

RESP1000

Preclinical

2 more assets in the full pipeline.

Partnerships

Currently seeking partners for clinical advancement and commercialization of VAL001; no major partnerships publicly disclosed yet

Beyond the preview

Go deeper on Respiratorius AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Respiratorius AB.